[Immune-Mediated Cerebellar Ataxias]

Area of Science:

• Neuroimmunology
• Cerebellar Disorders
• Autoimmune Diseases

Background:

• Autoimmune mechanisms can damage the cerebellum, leading to cerebellar ataxias (CAs).
• Immune-mediated cerebellar ataxias (IMCAs) encompass various conditions like gluten ataxia, postinfectious cerebellitis, paraneoplastic cerebellar degeneration (PCD), anti-GAD ataxia, and PACA.
• Pathogenic mechanisms include cell-mediated immunity in PCD and antibody-mediated synaptic dysfunction in anti-GAD ataxia.

Purpose of the Study:

• To review the spectrum of immune-mediated cerebellar ataxias (IMCAs).
• To discuss the underlying autoimmune mechanisms.
• To highlight the importance of early intervention and variable therapeutic benefits of immunotherapies.

Main Methods:

• Literature review of autoimmune cerebellar ataxias.
• Analysis of proposed pathomechanisms for different IMCA subtypes.
• Synthesis of information on therapeutic approaches and prognosis.

Main Results:

• IMCAs are a diverse group of cerebellar disorders triggered by autoimmune processes.
• Specific antibodies (e.g., anti-GAD65) can cause synaptic deficits by reducing GABA release.
• Therapeutic responses to immunotherapies are etiology-dependent.

Conclusions:

• Early diagnosis and intervention in IMCAs are vital for preserving cerebellar function.
• Understanding the specific autoimmune mechanisms is key to tailoring effective treatments.
• Immunotherapies offer variable benefits, emphasizing the need for personalized treatment strategies.